<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56881">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02365584</url>
  </required_header>
  <id_info>
    <org_study_id>A-93-52030-279</org_study_id>
    <nct_id>NCT02365584</nct_id>
  </id_info>
  <brief_title>Quality of Life in Patients With Inoperable Malignant Bowel Obstruction</brief_title>
  <acronym>QoL in IMBO</acronym>
  <official_title>A Phase II, Multicentre, Randomized Controlled Study Evaluating The Quality Of Life In Patients With Inoperable Malignant Bowel Obstruction Treated With Lanreotide Autogel 120 mg in Combination With Standard Care vs. Standard Care Alone (QOL IN IMBO STUDY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the impact on quality of life of
      Lanreotide Autogel 120 mg in combination with standard care, in comparison to the standard
      care alone, in subjects affected by inoperable malignant bowel obstruction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of Mean AUC Edmonton Symptom Assessment System (ESAS) Total Scores.</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single ESAS items symptom score.</measure>
    <time_frame>Baseline to day 7, day 14 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESAS total score.</measure>
    <time_frame>Baseline to day 7, day 14 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in general activity.</measure>
    <time_frame>Baseline, day 7, 14 and 28</time_frame>
    <description>Karnofsky performance status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in abdominal pain scores.</measure>
    <time_frame>Baseline, day 7, 14 and 28</time_frame>
    <description>Visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In patients without nasogastric tube (NGT), the number of patients experiencing ≤ 2 vomiting episodes/day during at least 3 consecutive days.</measure>
    <time_frame>Between day 1 to 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In patients with NGT removed, the number of patients with at least 3 consecutive days without vomiting recurrence.</measure>
    <time_frame>Baseline, day 7, 14 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In patients with a NGT, change in daily NGT secretion volume.</measure>
    <time_frame>Baseline, day 7, 14 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of daily vomiting episodes and number of days without vomiting.</measure>
    <time_frame>Baseline, day 7, 14 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in average number of bowel movements per day.</measure>
    <time_frame>Baseline, day 7, 14 and 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Intestinal Obstruction</condition>
  <arm_group>
    <arm_group_label>Standard care and Lanreotide Autogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard care according to site clinical practice and Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care according to site clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lanreotide (Autogel formulation)</intervention_name>
    <description>Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.</description>
    <arm_group_label>Standard care and Lanreotide Autogel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must demonstrate willingness to participate in the study and to be compliant
             with any protocol procedure.

          -  Provision of written informed consent prior to any study related procedure.

          -  Diagnosis of an inoperable malignant bowel obstruction, confirmed by appropriate
             imaging report.

          -  In case of peritoneal carcinomatosis, diagnostic confirmation by CT or MRI scan.

          -  Confirmed as inoperable after medical advice.

          -  Patient with a nasogastric tube or presenting with 3 or more episodes of vomiting
             every day in the last consecutive 48 hours.

          -  Patient life expectancy must be more than 14 days.

        Exclusion Criteria:

          -  Has operable obstruction or any sub-obstruction.

          -  Has bowel obstruction due to a non-malignant cause; (hypokaliaemia, drug
             side-effects, renal insufficiency, etc).

          -  Has signs of bowel perforation.

          -  Has prior treatment with somatostatin or any analogue within the previous 60 days.

          -  Has a known hypersensitivity to any of the study treatments or related compounds.

          -  Is likely to require treatment during the study with somatostatin or any analogue
             other than the study treatment.

          -  Is at risk of pregnancy or lactation, or is likely to father a child during the
             study. Females of childbearing potential must provide a negative pregnancy test at
             start of study and must be using oral or double barrier contraception. Non
             childbearing potential is defined as post-menopause for at least 1 year, surgical
             sterilisation or hysterectomy at least three months before the start of the study.

          -  Has any mental condition rendering the subject unable to understand the nature, scope
             and possible consequences of the study, and/or evidence of an uncooperative attitude.

          -  Has abnormal baseline findings, any other medical condition(s) or laboratory findings
             that, in the opinion of the Investigator, might jeopardise the subject's safety or
             decrease the chance of obtaining satisfactory data needed to achieve the objective(s)
             of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paola Mazzanti, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ipsen Recruitment Enquiries</last_name>
    <email>Clinical.trials@ipsen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale Sacro Cuore di Gesù, U.O.C. Oncologia Medica</name>
      <address>
        <city>Gallipoli</city>
        <state>Lecce</state>
        <zip>73014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ospedali riuniti Ancona- Dipartimento Medicina Interna - Clinica Oncologica</name>
      <address>
        <city>Ancona</city>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - di Aviano, Dip. di Oncologia Chirurgica- S.O.C. di Chirurgia Oncologica Generale</name>
      <address>
        <city>Aviano (Pordenone)</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Tumori &quot;Giovanni Paolo II&quot;- Istituto di Ricovero e Cura a Carattere Scientifico, U.O.C. DI ONCOLOGIA MEDICA</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Sacro Cuore di Gesù - Fatebenefratelli</name>
      <address>
        <city>Benevento</city>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospice Convento delle Oblate</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospice e Cure palliative - IRCCS AOU San Martino - IST</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Locale n ° 5 &quot;Spezzino&quot; Ospedale Felettino - Oncologia Via del Forno 4</name>
      <address>
        <city>La Spezia</city>
        <zip>19124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (I.R.S.T.) srl</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele IRCCS, Ginecologia oncologica</name>
      <address>
        <city>Milano</city>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori - Struttura Complessa di Cure Palliative, Terapia del Dolore e Riabilitazione</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Polo Universitario &quot;Luigi Sacco&quot;</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.R.N.A.S. P.O. Civico Benfratelli - Oncologia Medica</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Regionale San Carlo- Oncologia Medica</name>
      <address>
        <city>Potenza</city>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>January 29, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Intestinal Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
